Progress in improving cancer outcomes increasingly involves the use of precision medicine, which uses information about a person’s own genes or proteins to diagnose or treat diseases like cancer. Biomarker testing opens the door to precision medicine, including targeted therapies that can result in improved survivorship and better quality of life. **Maine has the opportunity to expand residents’ access to this potentially lifesaving testing.** LD 1577 would make it possible for more patients to get the right treatment at the right time. The following stories highlight the benefit of biomarker testing on patient care.
I was initially diagnosed with cancer at age 44. If I had biomarker testing then, I may have been able to avoid: the further spread of my cancer, the chemotherapy, and everything that came with it.

Diane is a three time cancer survivor. She was first diagnosed with uterine cancer at age 44, and she was treated with surgery. But years later, Diane was again in pain and knew something wasn’t right. She and her health care providers investigated, and she was diagnosed with ovarian cancer. She began a treatment plan that many cancer patients may expect: her providers surgically removed the tumor, and she began standard chemotherapy after the surgery. But Diane did not expect that three months into chemotherapy, her cancer would be back and have spread to her lymph nodes. Her prognosis was very poor, and she had few options. Her doctor ordered biomarker testing, and the results she received opened up treatment options Diane did not previously have. Her biomarkers showed she was a good fit for immunotherapy, and thankfully, Diane felt better within one treatment. She finished immunotherapy three years ago, and she is stable and cancer-free. Unfortunately, this effective treatment did not come without a cost. Diane’s Marketplace health insurance denied coverage of her biomarker testing, and she received a bill for $20,000. Luckily Diane received assistance from her testing provider for her life-saving biomarker testing, but not all cancer patients are so lucky.
I will never forget getting the call from my oncologist once the biomarker test results were back. She told me the results showed I would not need to do a course of chemotherapy. My relief at this news was incredible.

In 2013, after transferring to Husson University to complete her degree, Helen was diagnosed with breast cancer at her routine screening. She underwent a lumpectomy to remove the tumor. Helen’s doctor ordered biomarker testing on her tumor cells, and she told Helen that the lab doing the test would give her a call to discuss the cost, insurance coverage, and possibility of financial assistance. Helen was managing a heavy course load at Husson and a time-consuming commute to Bangor, and it was stressful for her to consider the need to juggle chemotherapy and ongoing health care costs in addition to that. Thankfully, her test results revealed that she had a low chance of cancer recurring and would not benefit from chemotherapy. If not for biomarker testing, it could have been impossible for Helen to finish a degree and progress her career at the same time as investing her time, energy, and money into more intensive treatment such as chemotherapy. Instead, her doctor ordered a round of radiation treatments for the late spring of 2014, and Helen takes oral medications to treat her breast cancer and prevent it from spreading. She graduated from Husson in May 2016, and she is happy and fulfilled in her career. She feels blessed to have the cancer journey she had thanks to biomarker testing.
Biomarker testing should be covered for every person who could benefit. I wonder how many women suffered through chemo and radiation when there might have been other options; I wonder how many women gave up believing those were their only choices.

When Mary Ann was diagnosed with breast cancer in 2016, she was all too familiar with the realities of living with cancer, having grown up as a caregiver to her father during his cancer treatment. Her cancer was discovered because of her recommended screenings, and she had her tumor surgically removed. Her breast cancer was treated with internal radiation, and she regained her health. But years later in 2022, her breast cancer came back. She underwent her second surgery, and this time her doctor ordered biomarker testing on the tumor to learn more about Mary Ann’s cancer and her treatment options.

Her test results indicated that Mary Ann would not benefit from additional chemotherapy or radiation, and she was so grateful that she did not elect to participate in those taxing procedures. Despite her biomarker testing results saving her from receiving ineffective, costly chemotherapy, one of the tests was not covered by her insurance. Thankfully, the biomarker testing company decided to cover the remainder of Mary Ann’s bill and save her from the great expense of preserving her livelihood, and she has become an advocate to ensure more cancer patients can access biomarker testing and understand their options.
Alex Babcock | Portland

“My insurance denied coverage of the biomarker testing on the grounds that it wasn’t necessary, when it literally saved my life.”

Alex is a hardworking member of her community, who tends to put her health on the backburner in favor of her career. When she started experiencing symptoms in 2018, she all but wrote them off - thinking “I’m just exhausted and stressed from work.” But finally, she visited her primary care provider later that year. After a chest x-ray revealed a mass on her lung, she had an emergency CT scan. Alex’s pulmonologist said based on her age and lack of risk factors that she likely had lymphoma, but if she had lung cancer there are tests that could help access the best treatment option and prognosis. Unfortunately, she was diagnosed with stage IV lung cancer.

Her pulmonologist recommended biomarker testing. The results didn’t come for weeks, and in that time Alex had started traditional chemotherapy and received a bill for $10,000 when her insurance denied coverage of her biomarker testing. While biomarker testing was deemed not necessary by her insurance company, it allowed Alex to access the right treatment for her. Her biomarker testing helped to identify the medication to treat her cancer, and it saved her life. Alex is still on that medication today, and she is stable. She is able to be the best mother and community member she can be thanks to her biomarker testing and the targeted treatment it led to.
With the initial diagnosis, I was feeling pretty hopeless – until they did biomarker testing. Later when the cancer progressed, I was prepared; I knew there were other drugs, other treatments, other possibilities for me. It was much less scary. Because I knew about my biomarkers.

In 2015, Corinne developed a severe cough and other symptoms that led to more frequent visits to her doctor’s office. At first she didn't think much of her symptoms, believing they may be a response to a recent house fire. Unfortunately by early 2016, Corinne’s condition had worsened. She went to a walk-in clinic for an x-ray, and the next day her doctor ordered a CT scan. It took a few weeks for Corinne to get a diagnosis, which caused significant distress. After further testing, she was diagnosed with lung cancer. Corinne called Dana-Farber Cancer Institute right away, and there she was able to get more detailed information about her cancer cells by undergoing biomarker testing.

She simultaneously received radiation as palliative care; her doctors were hoping it would shrink the tumor enough so that she could breathe easily. Unfortunately, due to her receiving that essential palliative care, insurance denied coverage of biomarker testing on the basis that she was already receiving treatment. But really, Corinne’s biomarker testing results guided her to begin treating her cancer with an effective targeted therapy drug that gave her life back. And over a year later when cancer spread to her brain, Corinne already had valuable information about her biomarkers that qualified her for the medication that has allowed her to live a happy life.
Biomarker testing is an important part of the process for many patients. It should be covered. You and your doctor need that information for your treatment, recovery and quality of life.

In 2021, at the same time as Kate and family welcomed a third child, she was diagnosed with breast cancer. She underwent surgery to have the tumor removed, and Kate vividly remembers one major decision made prior to the lumpectomy. There was a form that stood out. She recalls how the hospital took extra time explaining that the biomarker tests that could help inform her treatment "were expensive" and if their insurance did not cover the testing, they'd have to pay out-of-pocket. Without much discussion, they agreed, the risk not to have the test could be lifechanging.

Kate is not easily overwhelmed, but waiting for test results that would inform her cancer treatment protocol was difficult. Finally, the results became available, and they provided an essential roadmap for Kate's treatment plan - chemotherapy was not needed. Kate's treatment, after removal of the lump, was eight weeks of radiation and five years on an estrogen receptor medication. Kate's treatment plan was the solid footing that she had longed for since her diagnosis. The biomarker testing provided the details needed to survive her breast cancer.
Thank you to the cancer survivors across Maine who have shared their stories to contribute to this storybook.

Thank you to our partners at Free ME from Lung Cancer and Consumers for Affordable Health Care for helping to reach Mainers who have benefitted from biomarker testing and have important stories to share.